Clinical Trials Logo

Acquired Von Willebrand Disease clinical trials

View clinical trials related to Acquired Von Willebrand Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03613584 Active, not recruiting - Clinical trials for Acquired Von Willebrand Disease

Von Willebrand Factor Concentrate During ECMO Support

Start date: April 16, 2018
Phase: Phase 2
Study type: Interventional

During treatments with extracorporeal circuits such as extracorporeal membrane oxygenation (ECMO) degradation of high molecular weight (HMW) of von Willebrand factor (vWF) multimers occur leading to an acquired von Willebrand disease. This disease is associated with increased bleeding and requirement for the transfusion with allogenic blood products especially packed red blood cells (PRBCs). A continuous treatment with von Willebrand factor concentrate (vWFC) may restore the multimers and bleeding can be avoided. Therefore a randomized, double-blind, prospective, controlled, two-arm clinical trial was designed, comparing patients receiving vWFC versus placebo.